These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 21987739)

  • 21. Chimpanzee Adenovirus Vector Ebola Vaccine.
    Ledgerwood JE; DeZure AD; Stanley DA; Coates EE; Novik L; Enama ME; Berkowitz NM; Hu Z; Joshi G; Ploquin A; Sitar S; Gordon IJ; Plummer SA; Holman LA; Hendel CS; Yamshchikov G; Roman F; Nicosia A; Colloca S; Cortese R; Bailer RT; Schwartz RM; Roederer M; Mascola JR; Koup RA; Sullivan NJ; Graham BS;
    N Engl J Med; 2017 Mar; 376(10):928-938. PubMed ID: 25426834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
    Feng Y; Li C; Hu P; Wang Q; Zheng X; Zhao Y; Shi Y; Yang S; Yi C; Feng Y; Wu C; Qu L; Xu W; Li Y; Sun C; Gao FG; Xia X; Feng L; Chen L
    Emerg Microbes Infect; 2018 Jun; 7(1):101. PubMed ID: 29872043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
    Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
    Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.
    Farooq F; Beck K; Paolino KM; Phillips R; Waters NC; Regules JA; Bergmann-Leitner ES
    Sci Rep; 2016 Jun; 6():27944. PubMed ID: 27323685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
    Yang L; Sanchez A; Ward JM; Murphy BR; Collins PL; Bukreyev A
    Virology; 2008 Aug; 377(2):255-64. PubMed ID: 18570964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
    Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
    J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
    Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
    Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges.
    Wang D; Hevey M; Juompan LY; Trubey CM; Raja NU; Deitz SB; Woraratanadharm J; Luo M; Yu H; Swain BM; Moore KM; Dong JY
    Virology; 2006 Sep; 353(2):324-32. PubMed ID: 16820184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.
    Geisbert TW; Bailey M; Hensley L; Asiedu C; Geisbert J; Stanley D; Honko A; Johnson J; Mulangu S; Pau MG; Custers J; Vellinga J; Hendriks J; Jahrling P; Roederer M; Goudsmit J; Koup R; Sullivan NJ
    J Virol; 2011 May; 85(9):4222-33. PubMed ID: 21325402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
    Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
    Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
    Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
    Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
    Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal vaccination with ebola virus GP amino acids 258-601 protects mice against lethal challenge.
    Su QD; He SH; Yi Y; Qiu F; Lu XX; Jia ZY; Meng QL; Fan XT; Tian RG; Audet J; Qiu XG; Bi SL
    Vaccine; 2018 Oct; 36(41):6053-6060. PubMed ID: 30195490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
    Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
    PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
    Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse.
    O'Brien LM; Stokes MG; Lonsdale SG; Maslowski DR; Smither SJ; Lever MS; Laws TR; Perkins SD
    Virology; 2014 Mar; 452-453():324-33. PubMed ID: 24461913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
    Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
    J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.